Loading
NASDAQHealthcareBiotechnology
Latest quote
$3.39
+$0.22 · +6.94%
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Previous close
$3.39
+$0.22 · +6.94%
Regular session · ET · Market data may be delayed.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Day range
Current $3.39
52-week range
Current $3.39
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
40
Expensive
Sentiment
61
Bullish
Risk
45
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Day range
Current $3.39
52-week range
Current $3.39
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI13.82M0.00%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM7.89M0.01%78.27B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF5.31M0.01%95.4B USD0.05%$235+0.80%
State Street SPDR S&P Pharmaceuticals ETFXPH3.68M0.81%461.57M USD0.35%$64.65+1.60%
iShares Russell 2000 Growth ETFIWO2.73M0.02%13.97B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO2.37M0.01%18B USD0.06%$112.66+0.50%
AdvisorShares Psychedelics ETFPSIL2.11M4.51%46.85M USD1.84%$21.765+3.69%
Vanguard Health Care ETFVHT1.08M0.00%22B USD0.09%$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOAdvisorShares Psychedelics ETFPSILVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
